The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis

References

• Gan L, Lyu X, Yang X, et al. Application of angiotensin receptor-neprilysin inhibitor in chronic kidney disease patients: chinese expert consensus. Front Med (Lausanne). 2022;9:1. doi:10.3389/fmed.2022.877237.
   Web of Science ®Google Scholar
• Kuang H, Huang X, Zhou Z, et al. Sacubitril/valsartan in chronic kidney disease: from pharmacological mechanism to clinical application. Eur J Pharmacol. 2021;907:174288. doi:10.1016/j.ejphar.2021.174288.
   PubMed Web of Science ®Google Scholar
• Mehta R, Ning H, Bansal N, et al. Ten-Year risk-Prediction equations for incident heart failure hospitalizations in chronic kidney disease: findings from the chronic renal insufficiency cohort study and the Multi-Ethnic study of atherosclerosis. J Card Fail. 2022;28(4):540–11. doi:10.1016/j.cardfail.2021.10.007.
   PubMed Web of Science ®Google Scholar
• Joseph MS, Palardy M, Bhave NM. Management of heart failure in patients with end-stage kidney disease on maintenance dialysis: a practical guide. Rev Cardiovasc Med. 2020;21(1):31–39. doi:10.31083/j.rcm.2020.01.24.
   PubMed Web of Science ®Google Scholar
• Rangaswami J, McCullough PA. Heart failure in End-Stage kidney disease: pathophysiology, diagnosis, and therapeutic strategies. Semin Nephrol. 2018;38(6):600–617. doi:10.1016/j.semnephrol.2018.08.005.
   PubMed Web of Science ®Google Scholar
• House AA, Wanner C, Sarnak MJ, et al. Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(6):1304–1317. doi:10.1016/j.kint.2019.02.022.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula S, Langenickel T, Pal P, et al. Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor. Clin Pharmacokinet. 2017;56(12):1461–1478. doi:10.1007/s40262-017-0543-3.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of america. Circulation. 2017;136(6):e137–e161. doi:10.1161/cir.0000000000000509.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi:10.1093/eurheartj/ehw128.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa1409077.
   PubMed Web of Science ®Google Scholar
• Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-Neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation. 2020;142(13):1236–1245. doi:10.1161/circulationaha.120.047643.
   PubMed Web of Science ®Google Scholar
• Berg DD, Samsky MD, Velazquez EJ, et al. Efficacy and safety of sacubitril/valsartan in high-risk patients in the PIONEER-HF trial. Circ Heart Fail. 2021;14(2):e007034. doi:10.1161/circheartfailure.120.007034.
   PubMed Web of Science ®Google Scholar
• Voors AA, Gori M, Liu LC, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015;17(5):510–517. doi:10.1002/ejhf.232.
   PubMed Web of Science ®Google Scholar
• Niu CY, Yang SF, Ou SM, et al. Sacubitril/valsartan in patients with heart failure and concomitant End-Stage kidney disease. J Am Heart Assoc. 2022;11(18):e026407. doi:10.1161/jaha.122.026407.
   PubMed Web of Science ®Google Scholar
• Hsiao FC, Lin CP, Yu CC, et al. Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective Multi-Institutional study. Front Cardiovasc Med. 2022;9:794707. doi:10.3389/fcvm.2022.794707.
   PubMed Web of Science ®Google Scholar
• Zhou W, Yang X, Jin J, et al. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2023;56(1):181–190. doi:10.1007/s11255-023-03599-w.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919.
   PubMed Web of Science ®Google Scholar
• Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018;6(6):489–498. doi:10.1016/j.jchf.2018.02.004.
   PubMed Web of Science ®Google Scholar
• Sheng Y, Ma X, Liu Y, et al. Study on the efficacy of sacubitril/valsartan in patients with heart failure with preserved ejection fraction undergoing peritoneal dialysis. Cardiology. 2023;148(5):385–394. doi:10.1159/000531217.
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Momomura SI, Saito Y, et al. Efficacy and safety of sacubitril/valsartan in japanese patients with chronic heart failure and reduced ejection Fraction – Results from the PARALLEL-HF study. Circ J. 2021;85(5):584–594. doi:10.1253/circj.CJ-20-0854.
   PubMed Web of Science ®Google Scholar
• Chang HY, Feng AN, Fong MC, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. 2019;74(4):372–380. doi:10.1016/j.jjcc.2019.03.010.
   PubMed Web of Science ®Google Scholar
• Chang HY, Lin CC, Chao CJ, et al. Real-World experience of angiotensin receptor-neprilysin inhibition in reduced ejection fraction heart failure patients with advanced kidney disease. Mayo Clin Proc. 2023;98(1):88–99. doi:10.1016/j.mayocp.2022.06.007.
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen CC, Tseng CN, et al. Clinical outcomes of sacubitril/valsartan in patients with acute heart failure: a multi-institution study. EClinicalMedicine. 2021;41:101149. doi:10.1016/j.eclinm.2021.101149.
   PubMedGoogle Scholar
• Guo Y, Ren M, Wang T, et al. Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF. Front Cardiovasc Med. 2022;9:955780. doi:10.3389/fcvm.2022.955780.
   PubMed Web of Science ®Google Scholar
• Lee WC, Liao TW, Chen TY, et al. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease. Cardiovasc Drugs Ther. 2023 [cited 2023 Jan 7]. doi:10.1007/s10557-022-07421-0.
   Web of Science ®Google Scholar
• Tan NY, Deng Y, Yao X, et al. Renal outcomes in patients with systolic heart failure treated with sacubitril-valsartan or angiotensin converting enzyme inhibitor/angiotensin receptor blocker. Mayo Clin Proc Innov Qual Outcomes. 2021;5(2):286–297. doi:10.1016/j.mayocpiqo.2020.10.008.
   PubMedGoogle Scholar
• Pontremoli R, Borghi C, Perrone Filardi P. Renal protection in chronic heart failure: focus on sacubitril/valsartan. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):445–452. doi:10.1093/ehjcvp/pvab030.
   Google Scholar
• Chen X, Jin C, Xie L, et al. LCZ696 and preservation of renal function in heart failure: a meta-analysis of 6 randomized trials. Rev Cardiovasc Med. 2020;21(1):113–118. doi:10.31083/j.rcm.2020.01.2.
   Google Scholar
• Wang Y, Zhou R, Lu C, et al. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc. 2019;8(13):e012272. doi:10.1161/jaha.119.012272.
   Google Scholar
• Hsieh HL, Chen CY, Chen CH, et al. Renal protective effect of sacubitril/valsartan in patients with heart failure. Sci Rep. 2021;11(1):4593. doi:10.1038/s41598-021-84118-8.
   Google Scholar
• Kang H, Zhang J, Zhang X, et al. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis. Eur J Pharmacol. 2020;884:173444. doi:10.1016/j.ejphar.2020.173444.
   PubMed Web of Science ®Google Scholar
• Cho IJ, Kang SM. Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease. Kidney Res Clin Pract. 2021;40(4):555–565. doi:10.23876/j.krcp.21.900.
   PubMed Web of Science ®Google Scholar
• Valdivielso JM, Balafa O, Ekart R, et al. Hyperkalemia in chronic kidney disease in the new era of kidney protection therapies. Drugs. 2021;81(13):1467–1489. doi:10.1007/s40265-021-01555-5.
   PubMed Web of Science ®Google Scholar
• Haynes R, Judge PK, Staplin N, et al. Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation. 2018;138(15):1505–1514. doi:10.1161/circulationaha.118.034818.
   PubMed Web of Science ®Google Scholar
• Moorhouse RC, Webb DJ, Kluth DC, et al. Endothelin antagonism and its role in the treatment of hypertension. Curr Hypertens Rep. 2013;15(5):489–496. doi:10.1007/s11906-013-0380-1.
   PubMed Web of Science ®Google Scholar
• Thomas P, Dasgupta I. The role of the kidney and the sympathetic nervous system in hypertension. Pediatr Nephrol. 2015;30(4):549–560. doi:10.1007/s00467-014-2789-4.
   PubMed Web of Science ®Google Scholar
• Hu J, Yang Z, Chen X, et al. Thromboxane A(2) is involved in the development of hypertension in chronic kidney disease rats. Eur J Pharmacol. 2021;909:174435. doi:10.1016/j.ejphar.2021.174435.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yu H, Zhao X, et al. The effects of LCZ696 in patients with hypertension compared with angiotensin receptor blockers: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2017;22(5):447–457. doi:10.1177/1074248417693379.
   PubMed Web of Science ®Google Scholar
• Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705. doi:10.1161/hypertensionaha.113.02002.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao X, Huang H, et al. Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension. Clin Res Cardiol. 2023;112(7):855–867. doi:10.1007/s00392-022-02120-0.
   PubMed Web of Science ®Google Scholar